Predict, Engineer, Outcompete,
Pathogens.
Embedded Files
We're building the computational design platform for programmable precision antimicrobials
We are building E-Flame, an AI-enabled platform that turns pathogen data into engineered, receptor-targeted antimicrobial candidates.
The Problem
Antimicrobial discovery is too slow
Drug resistance is rising, while conventional antimicrobial discovery remains costly, slow and difficult to scale.
The next generation of antimicrobials must be easier to design, more precise in what they target, safe for the microbiome, and capable of responding to rapidly evolving pathogens.
Elakistos is building the computational infrastructure to make this possible.
According to the WHO, the rapid increase in antimicrobial resistance, could mean that by 2050, a simple sore throat could be fatal.
(WHO report 2022)
Scientific Foundation
Scientific Foundation
Nature already solved
Nature already solved
targeting.
targeting.
We are making it
We are making it
programmable.
programmable.
Our scientific foundation is built on tailocins—natural bacterial nanomachines that can kill specific harmful bacteria without disrupting the wider bacterial community in the way broad-spectrum antibiotics often do.
Built on our research into tailocin diversity, microbial competition and receptor recognition, E-Flame learns the biological patterns that allow tailocins to identify and kill specific bacteria. E-flame then uses those insights to generate new candidates, ready for laboratory validation.
Our Solution : E-Flame
Our Solution : E-Flame
We decode biological targeting.
E-Flame designs the candidate.
Every validated result expands the platform’s understanding of how antimicrobial structure relates to pathogen targeting, improving future candidate design.
*We are currently raising capital to develop E-Flame into a commercially viable product.
Looking to partner with us?
Together, we can build the next generation of precision antimicrobial therapies
Awards & Recognition
Awards & Recognition
We received a Fulbright grant in 2026 to accelerate the building of our AI-powered drug creation platform, E-flame. The research is conducted in collaboration with the University of Tennessee, USA.
Elakistos Biosciences was one of the few AI+Biotech start-ups selected to present a tech talk at the NEXT.BIO Conference at University of California, San Francisco in October 2025. The conference was a culmination of the 2025 Next Sequence accelerator program, that Elakistos participated in.
We were one of Bpifrance EuroQuity's top deeptech start-ups selected for their April 2025 SEADE DEEPTECH E-PITCH. Watch our 5-min pitch.
Elakistos Biosciences was awarded the best scientific research in the National Research Fund 2024 Kenya National Research Festival Poster Category.
Page updated
Report abuse